TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CARE-HF Long Term Follow-up

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have participated in the CARE-HF program and were reported to be alive in May 2005~* Patients who signed a patient data release consent form~Exclusion Criteria:~* Patients who have not participated in the CARE-HF program~* Patients with exclusion criteria required by local legislation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRT in CARE-HF (Type: None): In the CARE-HF study patients treated with standard medical treatment plus CRT were compared to patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.~CARE-HF LTFU study continued ot follow up the original CARE-HF CRT group patients.
- Control in CARE-HF (Type: None): In the CARE-HF study patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, almost all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.~CARE-HF LTFU study continued to follow up the original CARE-HF control group patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study (the LIQUID Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years old~2. Patients with STEMI (onset of pain\<12 hours) with indication for primary PCI~3. Informed consent obtained in writing~Exclusion Criteria:~Pregnancy/Breastfeeding~* Severe nausea or vomiting~* Treatment with a P2Y12 inhibitor within the previous 1 month~* Inability to give informed consent~* Hemodynamic instability~* Arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous antiarrhythmic agents~* Killip class ≥3~* Known hypersensitivity to ticagrelor~* History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 3 months.~* Other bleeding diathesis, or considered by investigator to be at high risk for bleeding~* Thombocytopenia (\<100.000 / μL) at randomization~* Anaemia (Hct \<30%) at randomization~* Polycytaemia (Hct \> 52%) at randomization~* Periprocedural IIb/IIIa inhibitor administration~* Thrombolysis administration~* Recent (\< 6 weeks) major surgery or trauma, including GABG.~* Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A inducers (rifampin /rifampicin, phenytoin, carbamazepine).~* Patients considered by the investigator to be at increased risk of bradycardiac events.~* Dialysis required.~* Severe uncontrolled chronic obstructive pulmonary disease~* Known severe hepatic impairement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor 180mg whole tablets (Type: ACTIVE_COMPARATOR): Ticagrelor 180mg loading dose, in the form of 2 whole tablets administered per os in the supine position (standard administration)
- Ticagrelor 180mg crushed and dispersed (Type: EXPERIMENTAL): Ticagrelor 180mg in the form of 2 tablets crushed and dispersed in purified water administered per os with 1-minute-stay in a 60-70 degrees semi-upright sitting position

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Maternal Depression and Promoting Infant Social-Emotional Health & Development

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mother is 18 years of age~* Mother speaks English~* Mother lives in metro-Atlanta area~* Mother has baby younger than 12 months of age~* Mother has positive depression screen (PHQ2)~Exclusion Criteria:~Stressors that mother specifies at the time of screening that would interfere with study participation such as: maternal homelessness, mental or physical health condition (diagnosed with schizophrenia or treatment/medication for hallucinations/delusions), current inpatient treatment for mental health or substance abuse. Infant exclusion criteria include factors that could render research participation stressful, such as intensive treatment for a genetic or health condition or not in permanent legal guardian custody

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mom & Baby Net (Type: EXPERIMENTAL): CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral
- Depression & Developmental Awareness System (Type: ACTIVE_COMPARATOR): Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Arterial pO2 8 kPa or lower, and arterial pCO2 7 kPa or higher.~* Base Excess 8 mmmol/l or higher.~* Written informed consent~Exclusion Criteria:~* Acetazolamide treatment regarded as obviously indicated or obviously contraindicated~* Already using acetazolamide~* Moribund patient~* Unable to give fully informed consent~* Allergy towards the tablet content or unable to swallow the tablets~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acetazolamide (Type: EXPERIMENTAL): Acetazolamide 250 mg Three times a day for five days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, one tablet Three times a day for five days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Magnetic Stimulation to Improve Speech in Aphasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Right Handed~* Single, Left Hemisphere Cerebrovascular Stroke~* Must be at least 6 months poststroke onset~* Native Speaker of English~* Clinical Diagnosis of Aphasia~Exclusion Criteria:~* Intracranial metallic body from prior neurosurgical procedure~* Implanted metallic devices: pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit or ventriculoperitoneal shunt~* Past history of seizure within 1 year~* Pregnancy~* History of substance abuse within last 6 months

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Real rTMS (Type: EXPERIMENTAL): These patients receive a series of 10 Real Transcranial Magnetic Stimulation, Repetitive (rTMS), treatments, only. There is pre-testing, and post-testing at 2 months after the last Real rTMS treatment.
- Sham rTMS (Type: SHAM_COMPARATOR): Patients receive a series of 10 Sham Transcranial Magnetic Stimulation, Repetitive (rTMS) treatments, followed by a series of 10 Real rTMS treatments. Sham rTMS treatments are identical to the Real rTMS treatments, however, no magnetic pulse is released. There is pre-testing, and post-testing at 2 months after the last Sham rTMS treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult women (aged 18 and older) with no upper age limit, who had a screening mammogram from January 1, 2019 to February 28, 2020.~* Able to read English~* Vision enough to read a newspaper~* Self-perception of their potential melanoma risk~* Willing to perform SSE either alone or with a skin check partner~* Willing to complete monthly surveys for 3 months and receive monthly text messages to personal mobile phone~* Have home Internet access and phone with ability to take a picture of a mole~* Have access to Federal Express or US Postal Service Express Mail to send mole self-sampling kits~* Willing to allow the research team access to their electronic health record to abstract physician assessment of concerning moles, biopsy results and treatment~* Willing to provide up-to-date email address, mailing address and telephone number~Inclusion criteria of skin check partner, who may be a man or a woman, to have mole self-sampled~* Male or female over the age of 18 years~* Able to read English~* Vision enough to read a newspaper~Exclusion Criteria:~* Male~* Female under the age of 18~* Unable to read English

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SSE educational intervention (Type: EXPERIMENTAL): Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
- Active control: Healthy Living (Type: ACTIVE_COMPARATOR): Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with first ever lacunar infarction within 7 days after the onset of symptoms~* Age: more than 45 years of age~Exclusion Criteria:~* Patients with any contraindications to the treatment with antiplatelet therapy~* Patients with potential cardiac embolic source; prosthetic valve, atrial fibrillation, atrial flutter, left atrial/atrial appendage thrombus, sick sinus syndrome, left ventricular thrombus, dilated cardiomyopathy, akinetic or hypokinetic left ventricular segment, atrial myxoma, Infective endocarditis, mitral valve stenosis or prolapse, mitral annuls calcification, left atrial turbulence, nonbacterial endocarditis, congestive heart failure, recent myocardial infarction (within 4 weeks)~* Bleeding diathesis~* Chronic liver disease (ALT \> 100 or AST \> 100) or chronic renal disease (creatinine \> 3.0mg/dl)~* Anemia (hemoglobin \< 10mg/dl) or thrombocytopenia (platelet count less than 100,000/mm3)~* Nonatherosclerotic vasculopathy; patients with clinical characteristics suggesting arterial dissection, moyamoya disease, Takayasu's arteritis, radiation associated angiopathy, and other vasculitis.~* Pregnant or lactating patients~* Patients with hyperthyroidism or COPD~* Patients with current anticoagulation or antiplatelet therapy~* Patients with poor temporal window in transcranial Doppler

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asprin (100mg) plus placebo (Type: PLACEBO_COMPARATOR): Asprin (100mg) plus placebo
- Asprin (100mg) plus cilostazol (200mg) (Type: ACTIVE_COMPARATOR): Asprin (100mg) plus cilostazol (200mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese Subjects with type 2 diabetes mellitus.~* Strictly/relatively treatment naïve Subjects with HbA1c ≥ 7.0% and ≤ 10%, or Subjects treated with single or two (less than half of the approved maximal dose for each) oral anti-hyperglycaemic agent with HbA1c ≤ 8%.~* Provision of informed consent.~Exclusion Criteria:~* Having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease.~* The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 1mg dapagliflozin
- 2 (Type: EXPERIMENTAL): 2.5mg dapagliflozin
- 3 (Type: EXPERIMENTAL): 5mg dapagliflozin
- 4 (Type: EXPERIMENTAL): 10mg dapagliflozin
- 5 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metacognitive Training to Enhance Strategy Use in Blast-Related TBI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 2 incidences of blast-related mTBI according to the American Congress of Rehabilitation Medicine, any of three following criteria:~  * loss of consciousness \<30 minutes, a Glasgow Coma Scale of 13~ * loss of memory for events immediately before and after the event (24 hours alteration of mental state at the time of accident)~ * focal neurological deficits that may, or may not, be transient (ACRM, 1993)~* Diagnosis must be documented in the medical record by a physician or neuropsychologist.~* Frontal Lobe impairment will be determined by 1.5 standard deviations below the mean on either the D-KEFS Color Word Interference Testorthe EXAMINER composite score.~* Age 18 to 55 years.~* At least 6 months post injury.~* Family member or friend that is willing to answer questionnaires and provide feedback on questionnaires and completion of homework.~Exclusion Criteria:~* History of pre-morbid learning disability.~* History of psychiatric diagnosis sufficiently severe to have resulted in inpatient hospitalization.~* Neurological disease unrelated to TBI (seizure disorder, stroke, ADHD).~* Score \< 90 on National Adult Reading Test.~* Failure of validity testing on the Test of Memory Malingering (TOMM)~* Reported alcohol or substance abuse within the past year, or such abuse documented in medical record.~* Reported involvement in current litigation.~* Changes within the past month of medications known to affect cognitive functions e.g. benzodiazepines, opioids, antidepressants and antipsychotics.~* Currently enrolled in other cognitive therapy that cannot be discontinued.~* Not fluent in English.~* Not competent to provide consent (also, not able to demonstrate understanding of expectations of study and potential risks of participation).~* Patients who receive \> 5 hours of therapy from a mental health specialist during the study will not be included in the final analysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Treatment Goal Management Training (Type: EXPERIMENTAL): Treatment Goal Management Training
- Arm 2: Control-Brain Health Workshop (Type: NO_INTERVENTION): Control-Brain Health Workshop

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 25-75 years old.~* Gender: female~* Newly diagnosed HER2 positive breast cancer patients who are scheduled to receive doxorubicin followed by trastuzumab adjuvant therapy.~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2~* Preserved LV systolic function in which the left ventricular ejection fraction (LVEF)≥50%.~* Patients with normal renal and hematological functions.~* Alanine amino transferase (ALT ≤ 3 times ULN).~Exclusion Criteria:~* Pregnant or lactating females.~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 2~* Patients with impaired LV systolic function in which the left ventricular ejection fraction (LVEF)\<50%.~* Patients with significant valvular heart disease, documented coronary artery disease, history of congestive heart failure or cardiomyopathy.~* Alanine amino transferase (ALT \> 3 times ULN).~* Patients already taking statins or other lipid lowering therapy.~* Patients with a known hypersensitivity to any of the used drugs.

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- control-group (Type: NO_INTERVENTION): This group will include 25 patients who will receive doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy.
- rosuvastatin-group (Type: ACTIVE_COMPARATOR): This group will include 25 patients who will receive doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy in addition to 20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Aged ≥12 years and older inclusive of either sex.~2. Documented clinical history of SAR (for at least 2 years preceding the Screening Visit \[Visit 1\]) with exacerbations (clinical evidence of active symptoms) during the study season for the mountain cedar pollen~3. A 12-hour reflective TNSS ≥ 8 out of a possible 12 and a congestion score of ≥ 2 for the AM assessment at the Screening Visit (Visit 1).~Key Exclusion Criteria:~1. Pregnant or lactating women.~2. Plans to travel outside the known pollen area for the investigative site for \> 24 hours during the last 7 days of run in period.~3. History of nasal polyps of other clinically significant respiratory tract malformations, recent nasal biopsy, nasal trauma (such as nasal piercing) or surgery, atopic dermatitis or rhinitis medicamentosa.~4. History of anaphylaxis and/or other severe local reaction(s) to skin testing.~5. History of positive test for HIV, Hepatitis B or Hepatitis C infection.~6. Documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip.~7. Subjects with an active pulmonary disorder or infection.~8. Subjects with posterior subcapsular cataracts or glaucoma.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSP 301 Placebo NS (Type: PLACEBO_COMPARATOR): None
- GSP 301-1 NS (QD) (Type: EXPERIMENTAL): None
- GSP 301-2 NS (BID) (Type: EXPERIMENTAL): None
- Olopatadine HCl-1 NS (QD) (Type: ACTIVE_COMPARATOR): None
- Olopatadine HCl-2 NS (BID) (Type: ACTIVE_COMPARATOR): None
- Mometasone Furoate-1 NS (QD) (Type: ACTIVE_COMPARATOR): None
- Mometasone Furoate-2 NS (BID) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed pancreatic ductal adenocarcinoma~* Administration of 2nd-line nab-paclitaxel plus gemcitabine~* Progression on 1st-line FOLFIRINOX~Exclusion Criteria:~* Pathologic diagnosis other than pancreatic ductal adenocarcinoma~* Administration of nab-paclitaxel plus gemcitabine as 3rd or greater lines of therapy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nab-P + GEM (Type: None): Nab-paclitaxel plus gemcitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete